Receptos, a biotech developing treatments for relapsing multiple sclerosis and IBD, raised $73 million by offering 5.2 million shares (up from 4.7 million) at $14, the low end of the range of $14 to $16. Receptos plans to list on the NASDAQ under the symbol RCPT. Receptos initially filed confidentially on 2/13/2013. Credit Suisse, Leerink Swann and BMO Capital Markets acted as lead managers on the deal.
